Fusion Antibodies Plc (FAB.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | -64 | -63 | -263 | -133 | 1,635 |
| Accounts receivable | -75 | 133 | 819 | -77 | -553 |
| Other Working Capital | 165 | -68 | 566 | 127 | -688 |
| Other Operating Activity | -1,390 | -1,771 | -2,876 | -242 | -1,530 |
| Operating Cash Flow | $-1,364 | $-1,769 | $-1,754 | $-325 | $-1,136 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10 | -2 | -114 | -258 | -365 |
| Other Investing Activity | 5 | 3 | 3 | 1 | 3 |
| Investing Cash Flow | $-5 | $1 | $-111 | $-257 | $-362 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 0 | 89 | 0 | 14 |
| Debt Repayment | -23 | -33 | -82 | -162 | -164 |
| Common Stock Issued | 555 | 2,808 | 0 | 116 | 2,815 |
| Other Financing Activity | -3 | -5 | -4 | -9 | -18 |
| Financing Cash Flow | $529 | $2,770 | $3 | $-55 | $2,647 |
| Exchange Rate Effect | 0 | 2 | 8 | N/A | N/A |
| Beginning Cash Position | 1,199 | 195 | 2,049 | 2,686 | 1,537 |
| End Cash Position | 359 | 1,199 | 195 | 2,049 | 2,686 |
| Net Cash Flow | $-840 | $1,002 | $-1,862 | $-637 | $1,149 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,364 | -1,769 | -1,754 | -325 | -1,136 |
| Capital Expenditure | -10 | -2 | -114 | -258 | -365 |
| Free Cash Flow | -1,374 | -1,771 | -1,868 | -583 | -1,501 |